At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
AZD1305 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-centre, Single-blind, Randomised, Placebo-controlled Phase IIa Study to Investigate the Effect of AZD1305 Given as an Intravenous (iv) Infusion on Left Ventricular Performance in Patients With Left Ventricular Dysfunction
In Brief
A Phase 2 clinical trial evaluating AZD1305 and Placebo for Left Ventricle Function. Completed, enrolled 16 participants across 1 site.
Detailed Summary
To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeft Ventricle Function
CountriesSweden
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedSep 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedSep 9, 2008
Enrollment StartAug 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.8 years ago
Interventions
AZD1305drug
iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Placebodrug
iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes